Actively Recruiting
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
Led by National Taiwan University Hospital · Updated on 2026-02-24
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
N
National Taiwan University Hospital
Lead Sponsor
N
National Taiwan University Hospital Hsin-Chu Branch
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different treatment modalities and drugs. The main questions it aims to answer are: 1. Investigators plan to correlate circulating tumor cells (CTC), circulating tumor emboli (CTM), and the composition of NK cells in CTM with clinical outcomes and establish their association with patient prognosis. 2. Investigators plan to understand the composition of NK cells and the immune cell components within CTM, and correlate these findings with treatment efficacy. Patients with recurrent/metastatic head and neck cancer will be included after informed consent and investigators will collect blood samples for analysis from them under the treatment provided by their primary care physicians.
CONDITIONS
Official Title
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2
- 20 years old or older
- Pathologically confirmed squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx that is recurrent or metastatic and not curable by local therapy
- At least one tumor lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Medical records during treatment are available
You will not qualify if you...
- Medical records during treatment unavailable
- Unable to cooperate with blood sampling
- Without informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University HsinChu Branch
Zhubei, HsinChu County, Taiwan, 302058
Actively Recruiting
Research Team
H
Hsu Wu, M.D.
CONTACT
W
Wei-Chen Lu, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here